Abstract
Aims Gastric cancer (GC) is often diagnosed at an advanced stage; inexpensive and valid biomarkers for GC are still unavailable. We aimed to evaluate the prognosis of the combination of pretreatment red cell distribution width (RDW) and neutrophil-to-lymphocyte ratio (NLR) in patients with GC. Methods A retrospective analysis from 103 GC patients who were diagnosed at our institution from 2012 to 2016 was performed. Both pretreatment RDW and NLR were calculated based on the recommended cutoff values of 13.4% and 2.755, respectively. Combined values of RDW and NLR (RDW + NLR) stratified patients into a score of 0 (RDW ≤ 13.4% and NLR ≤ 2.755), a score of 1 (RDW > 13.4% or NLR > 2.755), and a score of 2 (RDW > 13.4% and NLR > 2.755). Prognostic significances for overall survival (OS) and progression-free survival (PFS) were assessed. Results Pretreatment RDW + NLR was a significantly independent prognostic factor for OS and PFS. Moreover, high RDW + NLR was strongly related to age, tumor location, TNM stage, CA125, and CA199. In a subgroup analysis for patients with advanced gastric cancer (AGC), we observed that the level of RDW + NLR was markedly associated with OS and PFS. Conclusion Pretreatment RDW + NLR is a simple, inexpensive, and valid prognostic system to predict the survival in patients with GC, especially AGC.
Highlights
Gastric cancer (GC) is the fifth most frequent cancer and the third cause of cancer-related mortalities worldwide, with 951,600 new cases diagnosed and 723,100 deaths, accounting for 6.7% and 8.8% of all cancers [1]
Gastroenterology Research and Practice we retrospectively investigated the prognostic significance of pretreatment red cell distribution width (RDW) + neutrophil-tolymphocyte ratio (NLR) in patients with GC
To determine the optimal marker for GC patient prognosis, we investigated the prognostic value of RDW combined with
Summary
Gastric cancer (GC) is the fifth most frequent cancer and the third cause of cancer-related mortalities worldwide, with 951,600 new cases diagnosed and 723,100 deaths, accounting for 6.7% and 8.8% of all cancers [1]. A decline trend of incidence and mortality rates has been observed in GC [2, 3] which is due to the improvements in diagnoses and treatments [4,5,6]. Several serum systemic inflammation biomarkers, including NLR and RDW, have been shown to possess potential to predict survival in some cancers, such as lung cancer [17, 18], breast cancer [19], and colorectal carcinoma [20]. A study has reported the prognostic values of combining RDW with NLR (RDW + NLR) to predict survival in patients with epithelial ovarian cancer [21]. Studies regarding the prognostic values of RDW combined with NLR in patients with GC have not been reported. Gastroenterology Research and Practice we retrospectively investigated the prognostic significance of pretreatment RDW + NLR in patients with GC
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
